The world's first oral Putan, an oral form of selective vasopressin V2 receptor antagonist developed by Otsuka Pharm Pharmaceutical Co., Ltd., Japan, was approved by FDA in the United States on May 19, 2009 for the treatment of hypervolemic and normovolemic hyponatremia, including heart failure, liver cirrhosis and SIADH patients.

Our company has completed the technical development from intermediates to API, which can commercially provide the following high-purity intermediates and cooperate with customers to complete document registration and on-site audit.